SNY - Moderna's R&D Day Unveils Strategic Roadmap Beyond COVID Franchise: Goldman Sachs | Benzinga
On Wednesday, Moderna Inc (NASDAQ: MRNA) conducted an R&D Day event outlining its strategic initiatives across four key areas - Respiratory Vaccines, Latent/Other Vaccines, Oncology Therapeutics, and Rare Disease Therapeutics.
Regarding the pipeline, mRNA's Phase 3 seasonal influenza vaccine successfully met the non-inferiority threshold required for approval. This achievement involved higher HAI geometric mean titers and seroconversion rates for all A and B strains compared to GSK Plc's (NYSE: GSK) Fluarix, notes Goldman Sachs.
This progress removes obstacles and opens the path for a combination vaccine.
mRNA has set ambitious goals, aiming for up to 15 product launches across the ...